FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.
| Network | Scheme | Amount | Pay To |
|---|---|---|---|
| Base | exact | $0.25 USDC | 0x50ab...12fc |
| solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp | exact | 0.25 tokens | 985iFj...5KX1 |